BRYCE CAMPBELL: Open Payments
NPI 1023417037 · REXBURG, ID. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$499 in 26 payments from 12 companies in 2025. Trend: 2023 $67 · 2024 $174 · 2025 $499
Food & beverage: $499
| Company | Payments | Amount |
|---|---|---|
| Vanda Pharmaceuticals Inc. | 8 | $136 |
| ABBVIE INC. | 3 | $66 |
| Antares Pharma, Inc. | 3 | $56 |
| Novo Nordisk Inc | 3 | $53 |
| Lilly USA, LLC | 2 | $35 |
| Astellas Pharma US Inc | 1 | $31 |
| Axsome Therapeutics, Inc. | 1 | $27 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $24 |
| Aimmune Therapeutics, Inc. | 1 | $22 |
| Novartis Pharmaceuticals Corporation | 1 | $19 |
Products named: FANAPT, XYOSTED, QULIPTA, ZEPBOUND, Veozah, Auvelity, TRINTELLIX, ZENPEP.
Industry payments across ID — which companies pay providers there.
